Research programme: utrophin modulators - Summit / University of Oxford

Drug Profile

Research programme: utrophin modulators - Summit / University of Oxford

Alternative Names: SMT 022357

Latest Information Update: 07 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Oxford
  • Developer Summit Therapeutics; University of Oxford
  • Class Small molecules
  • Mechanism of Action Utrophin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 04 Oct 2016 Summit Therapeutics and Sarepta Therapeutics agree to co-develop utrophin modulators in Turkey, Common Wealth of Independent States and Europe for Duchenne muscular dystrophy
  • 17 Nov 2015 Summit Therapeutics extends its collaboration with University of Oxford for development of utrophin modulators for Duchenne muscular dystrophy
  • 30 Sep 2015 Pharmacodynamics data from preclinical study in Duchenne muscular dystrophy released by Summit Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top